natgillin/translations-raw huggingface dataset:
A body as claimed in any one of claims 1 to 7, wherein the formulation comprises a prime and at least one boost dose of the or each antigenic or immunogenic agent. 
Tijelo sukladno bilo kojem od patentnih zahtjeva 1 do 7, pri čemu ta formulacija obuhvaća glavnu i najmanje jednu poticajnu dozu tog ili svakog antigenog ili imunogenog sredstva.
A body as claimed in any one of Claims 1 to 8, wherein the or each antigenic or immunogenic agent is selected from the group comprising, killed, attenuated or combined micro-organisms, inactive toxic compounds, whole or fragments of proteins or polysaccharides, DNA and RNA. 
Tijelo sukladno bilo kojem od patentnih zahtjeva 1 do 8, pri čemu se to ili svako antigeno ili imunogeno sredstvo odabire iz skupine koja sadrži, uništene, oslabljene ili kombinirane mikroorganizme, neaktivne toksične spojeve, cijele ili fragmente proteina ili polisaharida, DNA i RNA.
A body as claimed in any one of claims 1 to 9, wherein the antigenic or immunogenic agent comprises or is Haemophilus influenza type b. 
Tijelo sukladno bilo kojem od patentnih zahtjeva 1 do 9, pri čemu antigeno ili imunogeno sredstvo obuhvaća ili je Hemofilna influenca tip b.
A body as claimed in claim 11, wherein the one or more excipients is/are selected from the group consisting of sugars, carbohydrates, stabilising agents, disintegrants and biodegradable polymers. 
Tijelo sukladno bilo kojem od patentnih zahtjeva 11, pri čemu se jedan ili više ekscipijenasa odabire iz skupine koja sadrži, ugljikohidrate, stabilizatore, dezintegrante i biorazgradive polimere.
A method for making the elongate body of any one of claims 1 to 14, the method comprising: 
Postupak izrade izduženog tijela sukladno bilo kojem od patentnih zahtjeva 1 do 14, taj postupak sadrži:
mixing the at least one active material and any excipients as dry material with a fluid to produce a paste; 
miješanje barem jednog aktivnog materijala i ekscipijenata kao suhog materijala sa fluidom da bi se proizvela ljekovita pasta;
ii) forming the paste; 
ii) formiranje ljekovite paste;
A method according to claim 15, wherein any excipients are mixed into a dry homogenous mix before being added to the active material and fluid. 
Postupak sukladno patentnom zahtjevu 15, pri čemu su svi ekscipijensi pomiješani u suhu homogenu smjesu prije nego što se dodaju u aktivni materijal i tekućinu.
A method according to claim 16, wherein some or all of the active material and some or all of one or more excipients are added to the fluid before mixing with the remaining dry material. 
Postupak sukladno patentnom zahtjevu 16, pri čemu se neki ili svi od aktivnih materijala i neki ili svi od jednog ili više ekscipijensa dodaju u tekućinu prije miješanja s preostalim suhim materijalom.
A method according to any one of claims 15 to 17, wherein the paste is formed by extrusion, tabletting or injection moulding. 
Postupak sukladno bilo kojem od patentnih zahtjeva 15 do 17, pri čemu se ta ljekovita pasta stvara ekstruzijom, tabletiranjem ili brizganjem u kalupu.
A packaged drug, for use with a drug delivery device, comprising the body as claimed in any one of claims 1 to 14, or produced by the method of claims 15 to 18, and a packaging. 
Upakirani lijek, namijenjen uporabi s uređajem za davanje lijeka, sukladno bilo kojem od patentnih zahtjeva 1 do 14, ili je proizveden postupkom sukladno patentnim zahtjevima 15 do 18, i pakiranje.
R2, R9, R10 and R11, independently of one another, are hydrogen, cyano, trifluoromethyl or methylamino; 
, R9, R10 i R11 su međusobno neovisno vodik, cijano, trifluorometil ili metilamino;
A compound for use according to claim 12, wherein the compound is administered in combination with an effective amount of an avermectin or milbemycin compound, more preferably, abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin, milbemectin, milbemycin D, moxidectin, nemadectin, a 5-oxo avermectin or milbemycin derivative, a 5-oxime avermectin or milbemycin derivative, or a combination thereof. 
Spoj za uporabu prema zahtjevu 12, naznačen time, da se spoj primjenjuje u kombinaciji s učinkovitom količinom spoja avermektina ili milbemicina, još poželjnije abamektina, dimadektina, doramektina, emamektina, eprinomektina, ivermektina, latidektina, lepimektina, selamektina, milbemektina, milbemicina D, moksidektina, nemadektina, 5-okso-avermektina ili derivata milbemicina, 5-oksim-avermektina ili derivata milbemicina, ili njihovih kombinacija.
PM01183, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, comprising administering a therapeutically effective amount of PM01183, or a pharmaceutically acceptable salt thereof, in synergistic combination with a therapeutically effective amount of a mitotic inhibitor, wherein the mitotic inhibitor is selected from paclitaxel, docetaxel, vincristine and vinorelbine. 
PM01183, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju raka, koja se sastoji u primjeni terapijski djelotvorne količine PM01183, ili njegove farmaceutski prihvatljive soli, u sinergističkoj kombinaciji s terapijski djelotvornom količinom protutumorskog antibiotika, gdje se protutumorski antibiotik bira između daunorubicina, doksorubicina, epirubicina, idarubicina, valrubicina, mitomicina C i aktinomicina D.
PM01183, or a pharmaceutically acceptable salt thereof, for use according to any preceding claim, wherein the mitotic inhibitor is paclitaxel. 
PM01183, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je protutumorski antibiotik doksorubicin.
The compound of claim 1 for use in the treatment of a mammal, including a human, having a disease or condition selected from the group consisting of autoimmune diseases; inflammatory diseases; autoinflammatory conditions; pain conditions; respiraratory, airway and pulmonary conditions; gastrointestinal (GI) disorders; allergic diseases; infection-based diseases; trauma and tissue injury-based conditions; fibrotic diseases; diseases driven by over-activity of IL1 pathways; ophthalmic/ocular diseases; joint, muscle and bone disorders; skin/dermatological diseases; renal diseases; genetic diseases; hematopoietic diseases; liver diseases; oral diseases; metabolic diseases, including diabetes (e.g. Type II) and complications thereof; proliferative diseases; cardiovascular conditions; vascular conditions; neuroinflammatory conditions; neurodegenerative conditions; cancer; sepsis; pulmonary inflammation and injury; or pulmonary hypertension. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen upotrebi u liječenju sisavca, uključujući čovjeka, koji ima bolest ili stanje kojeg se bira iz skupine koju čine autoimune bolesti; upalne bolesti; samoupalna stanja; bolna stanja; dišna, stanja dišnih puteva i plućna stanja; gastrointestinalni (GI) poremećaji; alergijske bolesti; bolesti uzrokovane infekcijama; traumatska i stanja uzrokovana ozljedom tkiva; fibrotične bolesti; bolesti uzrokovane hiperaktivnošću IL1 puteva; oftalmičke/očne bolesti; poremećaji zglobova, mišića i kostiju; kožne/dermatološke bolesti; bubrežne bolesti; genetičke bolesti; hematopoetske bolesti; bolesti jetre; bolesti usta; metaboličke bolesti, uključujući dijabetes (primjerice tip II) i njegove komplikacije; proliferativne bolesti; kardiovaskularna stanja; vaskularna stanja; neuroupalna stanja; neurodegenerativna stanja; rak; sepsa; upala i ozljeda pluća; ili plućna hipertenzija.
The compound of claim 1 for use according to claim 2 wherein the disease or condition is systemic lupus erthematosus (SLE), lupus nephritis, rheumatoid arthritis, psoriasis, atopic dermatitis, gout, cryopyrin-associated periodic syndrome (CAPS), diffuse large B cell lymphoma (DLBCL), chronic kidney disease or acute kidney injury, chronic obstructive pulmonary disorder (COPD), asthma or bronchospasm. 
Spoj u skladu s patentnim zahtjevom 1 namijenjen upotrebi u skladu s patentnim zahtjevom 2, naznačen time što je bolest ili stanje sistemni eritematozni lupus (SLE), lupozni nefritis, reumatoidni artritis, psorijaza, atopični dermatitis, giht, periodični sindrom povezan s kriopirinom (CAPS), difuzni limfom velikih B-stanica (DLBCL), kronična bolest bubrega ili akutna ozljeda bubrega, kronični opstruktivni plućni poremećaj (COPD), astma ili broncospazam.
The compound of claim 1 for use according to claim 3 wherein the disease or condition is rheumatoid arthritis. 
Spoj u skladu s patentnim zahtjevom 1 namijenjen upotrebi u skladu s patentnim zahtjevom 3, naznačen time što je bolest ili stanje reumatoidni artritis.
a second compound, the second compound being selected from the group consisting of a corticosteroid, hydroxychloroquine, cyclophosphamide, azathioprine, mycophenolate mofetil, methotrexate, janus kinase inhibitor, statin, calcipotriene, angiotensin-converting enzyme inhibitor and angiotensin receptor blocker; and an optional pharmaceutically acceptable carrier, excipient or diluents. 
drugi spoj, gdje se drugi spoj bira iz skupine koju čine kortikosteroid, hidroksiklorokin, ciklofosfamid, azatioprin, mikofenolat mofetil, metotreksat, inhibitor janus kinaze, statin, kalcipotrien, inhibitor angiotenzin-konvertirajućeg enzima i blokator angiotenzinskog receptora; i izborna farmaceutski prihvatljiva podloga, pomoćna tvar ili razrjeđivači.
The pharmaceutical combination of claim 11 wherein the janus kinase inhibitor is tofacitinib. 
Farmaceutska kombinacija u skladu s patentnim zahtjevom 11, naznačena time što je inhibitor janus kinaze tofacitinib.
CNS 7056 or the salt or solvate for use according to claim 1, wherein at least one top-up dose of CNS 7056 is given, preferably in the range of 1 to 4 mg/patient, more preferably between 1.5 and 3.5 and most preferably 2 or 3 mg/patient. 
CNS 7056 ili njegova sol ili solvat za primjenu sukladno zahtjevu 1, naznačen time što se daje najmanje jedna dopunska doza CNS 7056, a prvenstveno u obimu od 1 do 4 mg/pacijentu, još poželjnije između 1.5 i 3.5 i najpoželjnije između 2 ili 3 mg/pacijentu.
CNS 7056 or the salt or solvate for use according to claim 2, wherein the initial dose and the top-up doses of CNS 7056 are combined as follows: 
CNS 7056 ili njegova sol ili solvat za primjenu sukladno zahtjevu 2, naznačen time što se inicijalna doza i dopunske doze CNS 7056 kombiniraju kako slijedi:
CNS 7056 or the salt or solvate for use according to any of claims 2 to 4, wherein not more than six top-up doses of CNS 7056 are given. 
CNS 7056 ili njegova sol ili solvat za primjenu sukladno zahtjevu 2 do 4, naznačen time što se ne daje više od šest dopunskih doza CNS 7056.
CNS 7056 or the salt or solvate for use according to any of claims 1 to 7, wherein the sedation is induced within a procedural sedation, preferably an endoscopy, more preferably upper Gl endoscopy or colonoscopy. 
CNS 7056 ili njegova sol ili solvat za primjenu sukladno zahtjevima 1 do 8, naznačen time što se sediranje inducira u okviru proceduralnog sediranja, a prvenstveno radi provođenja endoskopije, još poželjnije endoskopije gornjeg GI ili kolonoskopije.
binding compound, comprising at least one C5 binding polypeptide according to any preceding claim; at least one albumin binding domain of streptococcal protein G, or a derivative thereof, and at least one linking moiety for linking said at least one domain or derivative thereof to the C or N terminal of said at least one C5 binding polypeptide. 
Spoj koji veže C5, koje sadrži najmanje jedan polipeptid koji veže C5 sukladno bilo kojem od prethodnih zahtjeva; najmanje jednu domenu za vezivanje albumina streptokoknog proteina G, i najmanje jednu veznu grupu za vezanje spomenutog najmanje jedne domene za C ili N terminal spomenutog najmanje jednog polipeptida koji veže C5.
The apparatus according to claim 1, wherein said at least one metal duct has a spiral shape. 
Aparat u skladu s patentnim zahtjevom 1, naznačen time, da najmanje jedna metalna cijev (2) ima spiralni oblik.
wherein R3a, R3b and Cy are as described in claim 1 . 
pri čemu su R3a, R3b i Cy opisani u patentnom zahtjevu 1.
for use in preventing and/or treating a lysosomal storage disorder in a patient at risk of developing or diagnosed with the same. 
naznačen time što je za uporabu za prevenciju i/ili liječenje poremećaja lizosomskog nakupljanja kod pacijenta s rizikom za razvoj ili dijagnozom istog.
A compound selected from: or a pharmaceutically acceptable salt or solvate thereof, or any combination of two or more thereof; for use in preventing and/or treating a lysosomal storage disorder in a patient at risk of developing or diagnosed with the same. 
Spoj naznačen time što je odabran od: ili njegova farmaceutski prihvatljiva sol, ili bilo koja kombinacija dva ili više; za upotrebu u prevenciji i/ili liječenju poremećaja lizosomskog nakupljanja kod pacijenta s rizikom za razvoj ili dijagnozom istog.
A compound for use according to 11, wherein at least one other therapeutic agent is imiglucerase or 1,5-(butylimino)-1,5-dideoxy-D-glucitol. 
Spoj za uporabu prema zahtjevu 7, naznačen time što je barem jedno drugo terapeutsko sredstvo imigluceraza ili 1,5-(butilimino)-1,5-dideoksi-D-glucitol.
wherein a compound of formula (4): is allowed to react with hydrogen in the presence of a 5% palladium/1% iron catalyst on carbon which is water-wetted, in a solvent, such as methanol for example, thereby providing a compound of formula (5). 
pri čemu je spoj s formulom (4): ostavljen da reagira s vodikom u prisutnosti 5% paladijevog/1% željezovog katalizatora na ugljiku koji je navlažen vodom, u otapalu, čime se dobiva spoj s formulom (5).
wherein a compound of formula (3): is allowed to react with ethylenediamine, optionally in the presence of N-bromosuccinimide, optionally in a solvent, such as dichloromethane for example, thereby providing a compound of formula (4). 
pri čemu je spoj s formulom (3): ostavljen da reagira s etilendiaminom, čime se dobiva spoj s formulom (4). Postupak prema zahtjevu 9, naznačen time što je navedeni korak A3 u prisutnosti N- bromosukcinimida.
thereby providing a compound of formula (2). 
dodavanje baze, čime se dobiva spoj s formulom (2).
wherein copanlisib, of formula (7): is allowed to react with hydrogen chloride, optionally hydrochloric acid, thereby providing copanlisib dihydrochloride (8): 
naznačen time što je kopanlisib, s formulom (7): ostavljen da reagira s hidrogen kloridom, čime se dobiva kopanlisib dihidroklorid (8):
A compound selected from: 
Spoj koji je odabran od: i
The pharmaceutical composition of claim 4, wherein the chimeric polypeptide has a half-life longer than a polypeptide consisting of the FVIII portion. 
Farmaceutski pripravak prema zahtjevu 4, naznačen time što kimerni polipeptid ima poluživot dulji od polipeptida koji se sastoji od dijela FVIII.
The pharmaceutical composition for use according to claim 11, wherein the surgery is minor surgery, major surgery, tooth extraction, tonsillectomy, inguinal herniotomy, synovectomy, total knee replacement, craniotomy, osteosynthesis, trauma surgery, intracranial surgery, intra-abdominal surgery, intrathoracic surgery, emergency surgery, or joint replacement surgery. 
Farmaceutski pripravak za uporabu prema zahtjevu 11, naznačen time što je operacija mala operacija, velika operacija, vađenje zuba, tonzilektomija, ingvinalna herniotomija, sinovektomija, cjelokupna zamjena koljena, kraniotomija, osteosinteza, operacija ozljede, intrakranijalna operacija, intraabdominalna operacija, intratorakalna operacija, hitna operacija, ili operacija zamjene zglobova.
A method according to claim 1, wherein a hub cap (6) is placed on each face of the wheel (10) prior to the step of moulding 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se ratkapu (6) stavlja na svaku površinu kotača (10) prije koraka oblikovanja.
A wheel with tyre according to any one of claims 12 to 14, wherein a hub cap (6) is sealed on each face of the wheel (10). 
Kotač s gumom u skladu s bilo kojim od patentnih zahtjeva 12 do 14, naznačen time što se ratkapu (6) zabrtvljuje na svaku površinu kotača (10).
PM01183, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, comprising administering a therapeutically effective amount of PM01183, or a pharmaceutically acceptable salt thereof, in synergistic combination with a therapeutically effective amount of an anticancer antibiotic, wherein the anticancer antibiotic is selected from daunorubicin, doxorubicin, epirubicin, idarubicin, valrubicin, mitomycin C and actinomycin D. 
PM01183, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju raka, koja se sastoji u primjeni terapijski djelotvorne količine PM01183, ili njegove farmaceutski prihvatljive soli, u sinergističkoj kombinaciji s terapijski djelotvornom količinom inhibitora mitoze, gdje se inhibitor mitoze bira između paklitaksela, docetaksela, vinkristina i vinorelbina.
PM01183, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, comprising administering a therapeutically effective amount of PM01183, or a pharmaceutically acceptable salt thereof, in synergistic combination with a therapeutically effective amount of a mitotic inhibitor, wherein the mitotic inhibitor is selected from paclitaxel, docetaxel, vincristine and vinorelbine. 
PM01183, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju raka, koja se sastoji u primjeni terapijski djelotvorne količine PM01183, ili njegove farmaceutski prihvatljive soli, u sinergističkoj kombinaciji s terapijski djelotvornom količinom inhibitora mitoze, gdje se inhibitor mitoze bira između paklitaksela, docetaksela, vinkristina i vinorelbina.
PM01183, or a pharmaceutically acceptable salt thereof, for use according to claim 7, wherein the cancer to be treated is selected from lung cancer, sarcoma, prostate cancer, gastric carcinoma, ovarian cancer, hepatoma, breast cancer, colorectal cancer, kidney cancer, brain cancer. 
PM01183, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 7, naznačen time što se rak kojeg treba liječiti bira između raka pluća, sarkoma, raka prostate, karcinoma želuca, raka jajnika, hepatoma, raka dojke, kolorektalnog raka, raka bubrega, raka na mozgu.
The compound according to claims 1-12 wherein R6-R10 are H with the proviso that one of the groups R7, R8 or Rg is the sulfonyl group with R1. 
Spoj prema zahtjevima 1-12, naznačen time što R6-R10 su H s uvjetom da je jedna od skupina R7, R8 ili R9 sulfonil skupina s R1.
The compound according to claim 13 wherein R8 is the sulfonyl group with R1. 
Spoj prema zahtjevu 13, naznačen time što R8 je sulfonil skupina s R1.
The compound according to claims 1-12 wherein R8 is the sulfonyl group with R1, and wherein R10 is methyl, and the remaining R6, R7 and R9 are H. 
Spoj prema zahtjevima 1-12, naznačen time što R8 je sulfonil skupina s R1, i pri čemu R10 je metil, i preostali R6, R7 i R9 su H.
The compound selected from claim 1 which is selected from the group of: 
Spoj odabran iz zahtjeva 1 koji je odabran od skupine:
A maleate salt of compound (I) represented by the following structural formula: 
Fumarat sol spoja (I) je predstavljena slijedećom strukturnom formulom:
wherein the molar ratio between compound (I) and maleic acid is 1:1. 
pri čemu je molarni odnos između spoja (I) i fumarne kiseline 1:1.
The maleate salt of claim 2, wherein at least 99% by weight of the maleate salt is single crystalline form A. 
Fumarat sol sukladno patentnom zahtjevu 1 ili 2, pri čemu je najmanje 99% težine soli u jednom kristalnom obliku.
compacting the lubricated blend to ribbons of density in a range of 1.1 to 1.2 g/ cm3 and sizing the compacted ribbons using a roller compactor, and 
zbijanje ovlažene smjese u trake gustoće u opsegu od 1.1 do 1.2 g/mL i formiranje do dane veličine zbijenih traka upotrebom valjak kompaktora,
a residual signal decoder (220) configured to restore a residual signal using the intra prediction mode; 
dekoder rezidualnog signala (220) konfiguriran za vraćanje rezidualnog bloka iz kvantiziranih rezidualnih koeficijenata;
A composition comprising one or more compounds of any one of claims 1-14, or one or more pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients. 
Pripravak naznačen time što sadrži jedan ili više spojeva iz bilo kojeg od zahtjeva 1-14, ili jednu ili više njihovih farmaceutski prihvatljivih soli, te jednu ili više farmaceutski prihvatljivih pomoćnih tvari.
A compound according to any one of claims 1 to 14, or pharmaceutically acceptable salt thereof, or a composition according to claim 16 for use in inhibiting glycogen synthase kinase 3 (GSK3) or casein kinase 1 (CK1) preferably wherein the GSK3 is in a cell; or preferably wherein the CK1 is in a cell; or preferably wherein the CK1 is CK1δ. 
Spoj prema bilo kojem od patentnih zahtjeva 1 do 14, ili njegova farmaceutski prihvatljiva sol, ili pripravak prema zahtjevu 16 naznačen time što je za uporabu za inhibiciju glikogen sintaza kinaze 3 (GSK3) ili kazein kinaze 1 (CK1) poželjno pri čemu GSK3 je u stanici; ili poželjno pri čemu CK1 je u stanici; ili poželjno pri čemu CK1 je CK1δ.
The compound for use, pharmaceutically acceptable salt for use, or composition for use according to claim 18, wherein the GSK3-mediated disorder is: 
Spoj za uporabu, farmaceutski prihvatljiva sol za uporabu, ili pripravak za uporabu prema zahtjevu 18, naznačen time što GSK3-posredovani poremećaj je:
a neurological disease, for example, a neurodegenerative disease, such as traumatic brain injury, Parkinson's disease, Huntington's disease, Alzheimer's disease, frontotemporal dementia, amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy, or corticobasal degeneration; or 
neurološka bolest, na primjer, neurodegenerativna bolest, kao što je traumatska ozljeda mozga, Parkinsonova bolest, Huntingtonova bolest, Alzheimerova bolest, frontotemporalna demencija, amiotrofna lateralna skleroza (ALS), progresivna supranuklearna paraliza, ili kortikobazalna degeneracija; ili
a psychiatric disorder; for example, bipolar disorder, schizophrenia, depression, or post-traumatic stress disorder; or 
psihijatrijski poremećaj; na primjer, bipolarni poremećaj, shizofrenija, depresija, posttraumatski stresni poremećaj; ili
Type II diabetes. 
dijabetes tipa II.
a psychiatric disorder; for example, autism or Fragile X syndrome; or 
psihijatrijski poremećaj; na primjer, autizam, ili sindrom fragilnog X; ili
The compound for use, pharmaceutically acceptable salt for use, or composition for use according to claim 18, wherein the GSK3-mediated disorder is acute lymphocytic leukemia, chronic myelocytic leukemia, chronic lymphocytic leukemia, or multiple myeloma. 
Spoj za uporabu, farmaceutski prihvatljiva sol za uporabu, ili pripravak za uporabu prema zahtjevu 18, naznačen time što je GSK3-posredovani poremećaj akutna limfocitna leukemija, kronična mijelocitna leukemija, kronična limfocitna leukemija, ili multipli mijelom.
a psychiatric disorder; for example, bipolar disorder, schizophrenia, depression, post-traumatic stress disorder, autism, or Fragile X syndrome; or 
psihijatrijski poremećaj; na primjer, bipolarni poremećaj, shizofrenija, depresija, posttraumatski stresni poremećaj, autizam, ili sindrom fragilnog X; ili
is either absent or selected from Pro, Dhb, (me)Lan,; 
nije prisutan ili je odabran od Pro, Dhb, (me)Lan;
is the C-terminus and is either absent or is Phe, unless X13 is absent; 
je C-terminus i nije prisutan ili je Phe, osim ako X13 nije prisutan;
with the proviso that: 
pod uvjetom da:
wherein said (methyl)Lanthionine bridge is of the size which comprises either two, three, four or five residues under the ring; 
pri čemu navedeni most (metil)Lantionina je veličine koja sadrži dva, tri, četiri ili pet ostataka ispod prstena;
or an amide, an ester or a salt thereof. 
ili njegov amid, ester ili sol.